SPY415.87+4.42 1.07%
DIA340.44+2.91 0.86%
IXIC14,038.76+180.92 1.31%

Arcus Biosciences Announces That It Has Dosed Its First Subject In Arc-10, A Phase 3 Study, Co. Says Dosing Of First Subject Triggers Milestone Payments To Wuxi Biologics Of $10M And Abmuno Therapeutics Of $5M

-Reuters

· 03/16/2021 16:32